It is done on both fronts. The US and Iran signed their deal overnight and it takes effect, with Trump vowing to release frozen funds and ease sanctions while Tehran keeps its ballistic missiles — the focus now swings to actually reopening the Strait of Hormuz (Goldman thinks flows recover to only ~70%). And Kevin Warsh delivered a hawkish debut: the Fed held at 3.50–3.75% on Wednesday but dropped its easing bias, eliminated forward guidance and published projections that lean toward at least one hike, sending Treasuries down and rate-hike bets surging. The net for stocks was risk-on anyway — the live Bloomberg ticker shows the S&P +1.21% and Nasdaq +1.34% with futures still climbing as the deal offsets the Fed. Crude bounced ~2% but sits near multi-month lows as the war premium gives way to glut talk; gold holds near $4,340; the 10-year is ~4.45%. A central-bank super-Thursday is ahead: BoE and Norges Bank both decide today, and US markets close tomorrow for Juneteenth.
Equity levels are Wednesday 17 June’s closes from the live Bloomberg “Top Securities” ticker read this morning; the 10-year, FX, crude and gold reflect the live overnight read. The swing factors from here: the Hormuz reopening logistics and the pace at which oil flows actually normalise, today’s BoE and Norges Bank decisions, and how far markets push the post-Warsh rate-hike pricing. US stock & bond markets are closed tomorrow (Fri 19) for Juneteenth.
Top of the morning
US–Iran deal is signed and takes effect — the hard part is reopening Hormuz
After four months of war, Washington and Tehran put pen to paper overnight. Trump says Iranians will get incentives and frozen funds released when they “behave,” and acknowledges Tehran keeps its ballistic missiles — fuelling the charge at home that the terms are softer than the 2015 accord. Attention now turns to the Strait: Goldman estimates Hormuz oil flows recover to only about 70% post-war, and shipowners are still diverting vessels to other countries for fuel as they wait for confidence the corridor is safe. A genuine de-escalation, but the logistics could take weeks.
Warsh rocks the bond market in his Fed debut — rate-hike bets surge
The FOMC left rates at 3.50–3.75% on Wednesday, but the new chair’s first meeting was anything but dovish: the statement scrapped its easing bias, forward guidance was eliminated, and the projections tilt toward at least one rate rise as officials vow to tame an inflation jolt running near double the 2% target after the Iran energy shock. Treasuries sold off and traders moved to price hikes rather than cuts. Warsh framed it as a “new chapter” with sweeping reforms to come — the regime question now is whether the Fed removes its policy anchor entirely.
Stocks climb anyway as the deal offsets the hawkish Fed
The live Bloomberg ticker has the S&P 500 at 7,420 (+1.21%) and the Nasdaq at 26,022 (+1.34%), with US futures still pointing higher this morning — the signed Iran deal and a relief that the Fed only held outweighing the hawkish projections. The FTSE 100 sits near 10,509 (+0.14%) ahead of the Bank of England. The tape’s message is that the equity risk-on and the bond sell-off can coexist: lower war premium and resilient growth, but a higher-for-longer rate path underneath.
G7 wraps at Versailles: Trump wants US arms made in Europe; KNDS IPO call today
Macron’s final G7 closed with the US president set to ask American defence companies to manufacture missiles in Europe, and Macron seeking a workaround to Trump’s ban on Anthropic’s AI models for European users. On the corporate side, German-French tankmaker KNDS holds a board meeting today to decide whether to proceed with one of Europe’s most anticipated IPOs — Berlin has confirmed it will take a 40% stake. Earlier G7 agreement to tighten Russian-energy sanctions still frames the supply backdrop.
The AI build-out keeps roaring — and keeps stretching how it’s financed
Meta is courting Wall Street, via Dina Powell McCormick, for financing once alien to Silicon Valley to fund a ~$600bn infrastructure push; Microsoft, in an exclusive, has built a sizeable business selling OpenAI models to Chinese companies despite the US–China AI rivalry; and a top Japan executive warned about “endlessly” funding $550bn of US infrastructure as domestic productivity lags. On the access side, JPMorgan followed Goldman in cutting off Anthropic’s Claude for its Hong Kong staff. Voracious demand, but increasingly debt- and policy-entangled.
A private-equity wipeout flashes a credit-cycle warning
Thoma Bravo will lose essentially all of the ~$5bn it put into customer-experience software group Medallia, handing the company to a Blackstone-led lender consortium that will inject $150mn to cut its debt — one of private equity’s biggest losses since 2008. It lands alongside Bloomberg’s read that private-credit turmoil has retail investors eyeing the exits, and Wall Street still lobbying to ease Basel capital rules. Idiosyncratic rather than systemic so far, but the kind of crack worth watching as rates stay high.
Central-bank super-Thursday: BoE and Norges Bank decide today
The Bank of England is widely expected to hold Bank Rate at 3.75% at noon London, weighing softer inflation against the Middle East energy risk; Norges Bank is closer to a coin toss on a first cut from 4.25%. They follow the BOJ, which lifted to a 31-year-high 1.00% this week — with Japan’s Nikkei pushing to record highs above 70,000 on AI and chip strength while Hong Kong lagged. A world of central banks edging away from easy policy even as growth signals wobble.
FT portfolio signal · tied to your holdings
What FT flagged for your book
Macro / regime read. FT’s feed sketches a higher-for-longer regime with a friendlier energy tail. The clearest signal is rates: Warsh’s first meeting dropped the bias to cut and his colleagues now project at least one hike to tame an Iran-driven inflation jolt running near double target — US government bonds dropped, the dollar is firmer (EUR/USD ~1.15, cable ~1.33), and duration caution is the order of the day. The offset is oil: FT’s framing has flipped from “$200 and shortages” to “looming gluts,” with Brent back under $80 even as ships still divert for fuel — energy disinflation that drains the stagflation tail but doesn’t soften the Fed. The flag most relevant to your war-chest discipline is credit: Thoma Bravo’s ~$5bn Medallia wipeout (handed to Blackstone-led lenders), private-credit outflows, and Wall Street pressing to ease Basel rules — froth and idiosyncratic stress, not yet a severe systemic trigger. Net: stance stays neutral-to-defensive, war-chest rules sheathed.
AI capex & semiconductors (theme — your semis/cloud shelf) · read-through to Microsoft, Alphabet, Amazon, ASML, Broadcom. Demand still looks voracious but the funding mix is the watch-item: Meta is reaching for Wall Street debt for a ~$600bn build, SpaceX’s $60bn Cursor deal and a Japanese warning on “endless” US-infrastructure funding round out a capex wave leaning on credit. Microsoft selling OpenAI models into China is an incremental AI-revenue positive but adds US–China policy risk; JPMorgan and Goldman curbing Anthropic in Hong Kong is a reminder the rails can be cut.
Berkshire Hathaway (held name) · sentiment. FT’s Robert Armstrong runs a pointed “what is the point of Berkshire?” piece — the post-Buffett question of whether it stays bold or drifts toward an index fund. No catalyst, but a narrative worth tracking for a core holding in a richly-valued, higher-rate market.
Payments (Visa, Mastercard) · slow-burn risk. Bloomberg’s Markets cover (cross-read) has Europe fighting to loosen America’s grip on payment systems and hunting alternatives to the US card networks on sovereignty grounds. No near-term catalyst, but a structural watch-item for the network duopoly.
Healthcare / GLP-1 (Novo Nordisk, Eli Lilly, UnitedHealth, Vertex) · quiet in FT today. No FT single-name items on the healthcare shelf — the medical action is in the clinical desk below (a cardiology-heavy NEJM issue, complement-targeted nephrology, an IPF first), with no GLP-1 readout in today’s feed.
Industrials / defence (Caterpillar, Deere) · mixed. A US push to make missiles in Europe and the KNDS IPO underscore a defence-capex tailwind; against that, BMW’s alarm over Chinese competition and softer global-cyclical demand temper the read for machinery exposure.
Shelf single-names live today: Berkshire Hathaway (FT think-piece, sentiment only). Everything else is theme-level — AI-compute demand set against a hawkish Warsh Fed, an oil slide FT now calls a coming glut, and a private-credit/PE stress flag.
Net: the relief is real — a signed deal and crude near multi-month lows ease the stagflation tail — but a hawkish Fed debut, a firmer dollar, and visible AI-credit and private-credit froth keep the regime neutral-to-defensive. No severe trigger, so war-chest rules stay sheathed. Watch-lines: Hormuz reopening pace and the “glut” call, today’s BoE & Norges Bank, post-Warsh rate-hike pricing, and AI-sector / private-credit funding supply.
Markets snapshot
Read this morning from the live Bloomberg “Top Securities” ticker. Equity indices are Wednesday 17 June closes; the 10-year, FX, crude and gold show the live overnight read. US futures were pointing higher pre-market as the signed Iran deal offset the hawkish Fed.
+1.9% bounce · still near multi-month low; glut talk
Gold (spot)
$4,338.90
+0.97% · holds firm near record
Levels transcribed from the Bloomberg Europe ticker this morning. The standout is that equities and bonds moved opposite ways — stocks up on the signed deal, Treasuries down as Warsh’s hawkish debut pushed traders to price hikes. Crude steadied with a small bounce but is still well off its war-premium highs; gold firm near record; the dollar a touch stronger. Next catalysts: the BoE and Norges Bank today, Hormuz reopening logistics, and tomorrow’s Juneteenth US close.
Global markets & macro
Wednesday belonged to Kevin Warsh, and his first FOMC meeting reset the rates regime. The Fed held at 3.50–3.75% but stripped out its bias to ease, eliminated explicit forward guidance, and published projections in which at least one further hike is now the central case — a response to inflation that the Iran war has driven to nearly double the 2% target. The bond market took the message immediately: yields jumped, the 10-year sits near 4.45%, and rate-hike odds have displaced the cuts that were priced only weeks ago. Warsh billed it as a “new chapter,” and the open question for markets is how far he goes in dismantling the Fed’s old guideposts. Equities, counter-intuitively, leaned the other way — the S&P closed up 1.21% and the Nasdaq 1.34% — because the simultaneous signing of the US–Iran deal pulled the war premium out of oil and revived the “resilient US” trade. A firmer dollar (EUR/USD ~1.15, sterling ~1.33 into the BoE) is the connective tissue: strong growth, higher-for-longer rates, lower energy risk.
Beneath the indices, the capital-markets plumbing keeps rewriting itself on credit. Meta is reaching into Wall Street debt markets — via former Goldman banker Dina Powell McCormick — to help fund a roughly $600bn infrastructure push, the latest sign the AI build-out is leaning on borrowing rather than cash flow; SpaceX’s $60bn Cursor deal and a senior Japanese executive’s warning about “endlessly” financing $550bn of US infrastructure point the same way. The confidence vote on compute is real, but it concentrates risk — and the cracks are visible elsewhere: Thoma Bravo’s near-total ~$5bn loss on Medallia (now handed to a Blackstone-led lender group) ranks among private equity’s worst since 2008, private-credit funds are seeing retail investors eye the exits, and banks are still pressing regulators to ease Basel capital rules. China is the other cross-current behind the cyclicals: BMW has sounded the alarm over Chinese competitors squeezing Europe’s carmakers at home and abroad, a reminder that the demand side is softer than the AI-capex headlines suggest.
Geopolitics & world news
The Middle East has moved from war to an uneasy peace. The US and Iran signed their agreement overnight; Trump has promised to release frozen Iranian funds and ease sanctions in exchange for “behaviour,” while conceding that Tehran retains its ballistic-missile arsenal — a concession his critics seize on to argue the deal is weaker than the 2015 accord it replaces. The market-relevant question is physical: reopening the Strait of Hormuz. Goldman estimates flows return to only about 70% of pre-war levels, and shipping bosses warn of continued disruption, with vessels still diverting to other countries to refuel until they trust the corridor. Oil has nonetheless shrugged off the crisis, with traders now fixated on a possible glut rather than a shortage. At Macron’s farewell G7 in Versailles, the agenda turned transatlantic and industrial: Trump is set to ask US defence firms to build missiles in Europe, Macron is seeking a way around Trump’s ban on Anthropic’s AI models, and leaders had earlier agreed to tighten sanctions on Russian energy.
The frictions further east and at home are sharper. Russian gasoline prices are skyrocketing as Ukraine’s drones keep hitting refineries; the EU’s leadership has been in contact with the Kremlin to test a peace track; and the UK political backdrop is unsettled, with Andy Burnham’s allies “quietly confident” of a Makerfield by-election win that would set up a leadership challenge to Keir Starmer. In tech-policy, the European drive for sovereignty rolls on — France’s spy agency has swapped Palantir for a local rival, and the Anthropic access dispute now sits at G7 level. For the markets reader, the throughline is a world simultaneously de-escalating its hot war and re-drawing its economic blocs. The clinical reader’s deep-dive follows below.
Clinical desk · NEJM this week
For the medical reader
Read this morning from the pinned NEJM current-issue eTOC feed (Vol 394, No 22, 11 June 2026) plus its ahead-of-print queue — a strongly cardiology-weighted issue: coronary imaging and physiology dominate, alongside a complement-targeted nephrology readout, a class-first in pulmonary fibrosis, a negative trauma trial, and a first-in-children gene therapy. Results, not just titles; numbers cross-checked against the NEJM abstracts and ACC 2026 / conference coverage.
OPTIMAL — IVUS- vs angiography-guided PCI in unprotected left main disease (neutral). In 806 patients at 28 high-volume centres in Italy, Spain and the UK (mean age 71, 35% diabetic), routine intravascular ultrasound did not beat angiography: the composite of death, MI, stroke or any revascularisation occurred in 33.7% with IVUS vs 30.9% with angiography (HR 1.11; no significant difference) over a median 2.9 years. Takeaway: in experienced, high-volume hands an angiography-led left-main strategy is defensible — IVUS as a selective tool, not a mandate.
ALL-RISE — AI-assisted angiography-derived FFR to guide PCI (positive; the AI angle). Across 1,930 patients in the US, Israel, Japan, Switzerland and the UK, an angiography-derived FFR computed by an AI tool (FFRangio) was non-inferior to the pressure-wire gold standard: the 1-year composite of death, MI or unplanned revascularisation was 6.9% vs 7.1%, while avoiding the wire and saving procedural time. A practical step toward wire-free physiology in the cath lab — and a real-world example of AI matching an invasive standard rather than just promising to.
APPLAUSE-IgAN — iptacopan in IgA nephropathy, final 24-month data (positive). In 478 adults with IgAN despite supportive care, the oral complement factor-B inhibitor iptacopan roughly halved the rate of kidney-function decline: annualised eGFR slope −3.10 vs −6.12 mL/min/1.73m²/yr (between-group +3.02; 95% CI 2.02–4.01; p<0.001), with proteinuria down 38.3% at nine months and a kidney-failure composite of 21.4% vs 33.5%. The trade-off is infection: serious infections ran 6.7% vs 2.1%, the expected signal when you block complement. A genuinely disease-modifying, complement-targeted option for IgAN.
TETON-2 — inhaled treprostinil for idiopathic pulmonary fibrosis (positive; a first for the class). In 593 IPF patients over 52 weeks, inhaled treprostinil slowed lung-function loss: median FVC decline −49.9 mL vs −136.4 mL on placebo (roughly 86–96 mL less decline), with clinical worsening in 27.2% vs 39%. With the replicate TETON-1 trial also hitting its primary endpoint, this is the first inhaled prostacyclin shown to modify IPF — a meaningful new lever alongside the antifibrotics for a disease with few good options.
SWiFT — prehospital whole blood in traumatic haemorrhage (neutral/negative). A pragmatic UK trial across 10 air-ambulance services tested up to two units of prehospital whole blood against standard blood components in life-threatening traumatic bleeding. Among roughly 600 patients transfused in the field, whole blood was not superior for the primary outcome of death or massive transfusion at 24 hours, with mortality numerically equal or higher at every timepoint through 90 days. A cold-water result for the prehospital whole-blood momentum — logistics and cost now have to justify themselves against no demonstrated survival edge.
Subretinal gene therapy for X-linked retinoschisis (landmark; first in children). A single subretinal injection of an AAV8 vector carrying the RS1 gene (scAAV8-hRS1) was given to one eye in 12 boys aged 5–18 with this inherited cause of childhood vision loss. The phase 1/2 read is a safety win — no grade ≥3 adverse events and no ocular inflammation — with visual acuity, OCT structure, electroretinography and microperimetry tracked to 52 weeks. Early, small, and uncontrolled, but it clears the key hurdle (delivery without inflammation) and warrants further testing in a condition with no approved therapy.
Public-health flag — first reported human H5N5. NEJM details the world’s first known human infection with highly pathogenic avian influenza A(H5N5): a fatal case in an older adult with comorbidities in Grays Harbor County, Washington, who kept backyard poultry exposed to wild birds, with onset in late October and confirmation in November 2025. A single zoonotic case with no human-to-human spread — but a reminder to keep avian-influenza exposure on the differential and worth a glance for anyone tracking pandemic-preparedness names.
Also in the issue and ahead-of-print queue: 10-year data on early surgery for asymptomatic severe aortic stenosis; apixaban vs rivaroxaban bleeding in acute VTE; SirPAD (sirolimus-coated balloon angioplasty for below-the-knee PAD) and a companion angiography-derived-physiology paper; a review on antidotes for anticoagulation reversal; IL-10 autoantibodies and HLA in IBD; obexelimab in IgG4-related disease and IL-17A targeting in PMR/giant-cell arteritis; a “major step toward a hepatitis B cure”; precision intensification in metastatic prostate cancer; TRACTION (tranexamic acid in surgery); an Andes hantavirus outbreak update; and a pointed Perspective pair on the dangers of dosing drugs on the basis of race as biology.
Provenance: read this morning from Luca’s pinned NEJM RSS tabs via Control Chrome — the current-issue eTOC feed (Vol 394, No 22, 11 June 2026, plus ahead-of-print) carried the cardiology load after the cardiology tab returned a search redirect. Trial numbers cross-checked against NEJM abstracts and ACC 2026 / Healio / TCTMD / CIDRAP coverage. Summarised, not reproduced verbatim; not clinical advice.
Today & week ahead (CET)
Thu 18Bank of England decision — 1pm Rome (hold at 3.75% expected) · Norges Bank decision (~50/50 on a first cut from 4.25%) · KNDS board votes on its IPO · US weekly jobless claims & Philly Fed · US–Iran deal implementation / Hormuz reopening logistics · G7 Versailles wrap